Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

Future Oncology

Volumn 9, Issue 7, 2013, Pages 955-957

  Bighin, Claudia ^a   Pronzato, Paolo ^a   Del Mastro, Lucia ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

HER 2 positive metastatic breast cancer; trastuzumab emtansine

Indexed keywords

ANTIBODY CONJUGATE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HER 2 POSITIVE METASTATIC BREAST CANCER; HUMAN; MICROTUBULE ASSEMBLY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAYTANSINE; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84880229916     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.74     Document Type: Article

References (5)

1. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
2. Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomised study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31(9), 1157-1163 (2013).
3. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012).
4. Anderson M, Lidbrink E, Bierre K et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J. Clin. Oncol. 29(3), 264-271 (2011).
5. Ellis PA, Barrios CH, IM Y et al. MARIANNE: A Phase III, randomized study of trastuzumab-DM1 (T-DM) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of her2-positive, progressive or reccurent locally advanced or metastatic breast cancer (MBC). J. Clin. Oncol. 29, 7S (2011).